{"id":"W4414094800","doi":"10.1016/j.annonc.2025.08.3757","title":"Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Ipsen; Gilead Sciences; Bayer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; GlaxoSmithKline; Amgen","keywords":"Pembrolizumab; Adenoid cystic carcinoma; Phases of clinical research; Carcinoma; Melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001074849,0.001439988,0.002174288,0.000656179,0.0005072184,0.001234355,0.000963859,0.001271147,0.004002116],"category_scores_gemma":[0.0005879648,0.0007650145,0.001566631,0.0005498352,0.001141392,0.001126184,0.0003618099,0.005088802,0.001070422],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00140976,"about_ca_system_score_gemma":0.001861476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002284207,"about_ca_topic_score_gemma":0.005308515,"domain_scores_codex":[0.9996334,0.0001144143,0.00001477373,0.00007098934,0.00003818449,0.0001282221],"domain_scores_gemma":[0.9996156,0.00004633479,0.00005532105,0.00003649256,0.00002336811,0.0002229413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6661455,0.1160484,0.004710659,0.0008803645,0.001950244,0.0003289514,0.0005006777,0.006806097,0.07289895,0.0008522612,0.009328475,0.1195494],"study_design_scores_gemma":[0.5299496,0.4459991,0.0116319,0.00004359915,0.0006460116,0.0002730173,0.0001402292,0.001830178,0.004776784,0.0004051259,0.004251259,0.00005321495],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906571,0.002121157,0.0005025868,0.0007466914,0.0002079025,0.001757795,0.00132819,0.0001436505,0.002534867],"genre_scores_gemma":[0.9888639,0.00167919,0.001376404,0.0009745728,0.0001429814,0.001585496,0.002126021,0.00003426709,0.003217057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004002116,"threshold_uncertainty_score":0.01338845,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009787600156352473,"score_gpt":0.3268003003395209,"score_spread":0.3170127001831684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}